How are Cosmetic Products Regulated in India?
The different expectations and needs of consumers are continually changing and therefore the cosmetic industry needs to be gradually evolve to meet the new consumer's demand. In this regard, India has recently introduced some regulatory updates to ensure that cosmetics placed on the market are safer for all consumers.
Picture of Marta Pinto

Marta Pinto

Regulatory Affairs Associate


The Drugs and Cosmetics Act 1940 and the Drug and Cosmetic Rules 1945 have regulated cosmetic products in India for years. According to the Drugs and Cosmetics Act 1940, a cosmetic is defined as “any article intended to be rubbed, poured, sprinkled or sprayed on, or introduced into, or otherwise applied to, the human body or any part thereof for cleansing, beautifying, promoting attractiveness or altering the appearance, and includes any article intended for use as a component of cosmetic”.

The manufacture of cosmetics is regulated under a system of inspection and licensing by the State Licensing Authorities appointed by the respective State Governments. Import of cosmetics into India is regulated through a system of registration by the Central Drugs Standard Control Organization (CDSCO) under the provisions of the Drugs and Cosmetics Act, 1940 and the Cosmetics Rules, 2020. CDSCO is the main regulatory authority for the cosmetics industry.

If a product falls within the definition of cosmetic (under the 1940 Act), it is required to be registered along with pack size, variant(s) and manufacturing premises before it is imported into the country. If a cosmetic product is not registered under the existent rules, it cannot be imported to India. On the other hand, if a cosmetic product does not comply with the specifications set out and the standards of quality or safety, it cannot be imported or manufactured in India.


False or misleading claims (implicit or explicit) are not allowed in cosmetic products made available in the Indian market. Products that have been tested in animals cannot be imported to India. It is also not allowed to manufacture or import cosmetics that contain hexachlorophene, lead, arsenic and mercury compounds.

The name of the cosmetic, name and address of the manufacturer and the country where the product was manufactured, directions for safe use, batch number, manufacturing license number, among other details, need to be placed in the label of cosmetic products. There are special labelling requirements for hair products containing dyes, colours and pigments (e.g., para-phenylenediamine) and for toothpaste containing fluoride.

The requirements for the use of ingredients in cosmetic products are stipulated on the “Classification of Cosmetic Raw Materials and Adjuncts” issued by the Bureau of India Standards (BIS). Ingredients are classified into two categories: Generally Recognized As Safe (GRAS) and Generally Not Recognized As Safe (GNRAS).

A positive list of dyes, colours and pigments allowed in cosmetics is provided by BIS (GRAS class). It is prohibited to manufacture or import cosmetics that contain dyes, colours and pigments that are not specified by the BIS. For other ingredients, the BIS usually considers them to be part of the GRAS class. The BIS also publishes a negative list of raw material which shall not form part of the composition of cosmetic products, along with a list of substances which cosmetic products shall not contain except subject to restrictions and conditions laid down.


In December 2020, India released and implemented the ‘Cosmetic Rules 2020’, under the provisions of the Drugs and Cosmetics Act 1940. It lays down guidelines for importation, manufacture, registering, labelling, packaging, testing, sale and distribution of cosmetics. The rules consist of 72 rules, 13 schedules and 24 appendixes.

The concept of “new cosmetic” was introduced for the first time. According to the new regulation, the term ‘new cosmetic´ refers to “cosmetic which contains novel ingredient and has not been used anywhere in the world or is not recognized for use in cosmetics in any National and International literature”. A prior permission from the Central Licensing Authority (CLA) and submission of data about the products’ safety and efficacy is required when manufacturing or importing a new cosmetic.

The Cosmetic Rules 2020 has simplified application, reducing the duplication of regulatory processes and formalities for identical products and brands. Compliance with Good Manufacturing Practices (GMP) and other guidelines need to be self-declared by the applicant of the registration.

Products manufactured outside India need to comply with the Cosmetics Rules 2020 (formulation, label and claims) and need to be registered through the e-Governance portal (SUGAM). If the manufacture, sale or distribution of a product is prohibited in the country of origin, it cannot be imported to India.

Other changes have been implemented by the Cosmetic Rules 2020, but in order to ensure a smooth transition, all the licenses that were granted under the former Drugs and Cosmetics Rules 1945 will remain valid until they expire or for a period of 18 months (from the date of the beginning of the new regulation), whichever comes later.

Critical Catalyst has a team of regulatory experts that can help you understand the particular requirements of Asian and Indo-Pacific markets. If you have any question, do not hesitate to contact us at


  1. Cosmetics. Central Drugs Standard Control Organization. Directorate General of Health Services. Ministry of Health &Family Welfare. Government of India. Available at:
  2. India Cosmetic Regulation. Chemlinked. 2020. Available at:


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »